SCHEMBL4894700

SCHEMBL4894700

Cc1cccc[n+]1CC(=O)c1cccc(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.56
KMT2A Q03164 6/20 0.56
KDM4E B2RXH2 7/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 4/20 0.46
HPGD P15428 3/20 0.46
HTT P42858 3/20 0.46
TSHR P16473 3/20 0.46
NPC1 O15118 2/20 0.46
LMNA P02545 2/20 0.46
ALOX12 P18054 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
KCNH2 Q12809 1/20 0.45
RAB9A P51151 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
GLA P06280 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL3883473 0.99 THRB (0.58) THRBKMT2AKDM4EMAPTMEN1
Bromide SCHEMBL3891677 0.84 THRB (0.61) THRBKMT2AKDM4EMAPTMEN1
SCHEMBL4896174 0.84 KMT2A (0.68) THRBKMT2AKDM4EMEN1NPC1
SCHEMBL13394254 0.83 KMT2A (0.70) THRBKMT2AKDM4EMEN1NPC1
SCHEMBL4890283 0.83 THRB (0.56) THRBKMT2AKDM4EMAPTMEN1
Bromide SCHEMBL3884195 0.82 KMT2A (0.70) THRBKMT2AKDM4EMEN1LMNA
Bromide SCHEMBL3896616 0.82 THRB (0.58) THRBKMT2AKDM4EMAPTMEN1
Bromide SCHEMBL1645919 0.82 KMT2A (0.73) THRBKMT2AKDM4EMEN1NPC1
SCHEMBL4895899 0.80 GSK3B (0.54) THRBKMT2AKDM4EMAPTMEN1
Bromide SCHEMBL3885368 0.79 THRB (0.55) THRBKMT2AKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 THRB 2955/4885KMT2A 603/4885KDM4E 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.